1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 3: 
Conservative treatment of 83 patients with subtotal central retinal artery occlusion
Pentoxifyllin InfusionsHemodilutionAspirinAcetacolamide (Diamox)Rheomacrodex InfusionsHeparinEye Drops for Lowering Eye PressureParacentesis
29 (34.9%)46 (54.21%)28 + 1 Plavix + 1 Tiklyd: 30 (36.14%)9 (10.84%)8 (9.64%)16 (19.28%)11 (13.25%)13 (15.66%)
Additional treatment or single treatment
Pentoxifyllin + additional treatment*: 21 patients (25.3%)Pentoxifyllin + additional treatment†: 36 (43.37%)Aspirin + additional treatment‡: 25 (30.12%)Acetacolamide + additional treatment§: nine (10.84%)Rheomacrodex + additional treatment§§: eight (9.64%)Heparin + additional treatment: 14 (16.87%)Eye drops + additional treatment: 11 (13.25%)Paracentesis + additional treatment: 11 (13.25%)
Pentoxifyllin only: eight patients (9.64%)Hemodilution only: 10 (12.05%)Aspirin only: five (6.02%)Acetacolamide onlyRheomacrodex onlyHeparin only: two (2.41%)Eye drops onlyParacentesis only: two (2.41%)
  • Note.—In all patients, immediate massage of the globe and treatment of high blood pressure were performed.
  • * Pentoxifyllin + aspirin, five (6.02%) patients; Pentoxifyllin + Diamox, one (1.2%) patient; Pentoxifyllin + aspirin + Diamox, one patient; Pentoxifyllin + Rheomacrodex, two (2.41%) patients; Pentoxifyllin + hemodilution, one patient; Pentoxifyllin + Paracentesis, three (3.61%) patients; Pentoxifyllin + hemodilution + aspirin + paracentesis, one patient; Pentoxifyllin + eye drops + paracentesis, two (2.41%) patients; Pentoxifyllin + hemodilution + eye drops + paracentesis, one patient; Pentoxifyllin + hemodilution + aspirin + heparin: one patient; Pentoxifyllin + Diamox + Rheomacrodex + paracentesis, one patient; Pentoxifyllin + hemodilution + eye drops, one patient; Pentoxifyllin + Diamox + paracentesis, one patient.
  • † Hemodilution + aspirin, 12 (14.45%) patients; hemodilution + eye drops, three (3.61%) patients; hemodilution + heparin, 10 (12.05%) patients; hemodilution + aspirin + heparin, one (1.2%) patient; hemodilution + aspirin + eye drops, one patient; hemodilution + Diamox + Rheomacrodex + paracentesis, one patient; hemodilution + aspirin + Diamox + heparin, one patient; hemodilution + eye drops + Diamox, one (1.2%) patient.
  • ‡ Aspirin + Heparin, one patient; aspirin + Rheomacrodex, one patient.
  • § Diamox + Rheomacrodex + eye drops, two patients.
  • §§ Rheomacrodex + paracentesis, one patient.